SUPPLEMENTAL METHODS - CONFLICT OF INTEREST STATEMENT (COI)

RRM serves as a consultant and an advisory board member for Astrazeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Pfizer, Merck, Novartis, Sanofi, and Tempus. RRM also receives institutional research funding from Bayer and Pfizer. CEK performs a consulting or advisory role with Exelixis and receives research funding from Sanofi, AVEO, EMD Serono, Janssen Oncology, and Sanofi. TKC receives support for research, advisory board membership, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi, Surface Oncology, Takeda, Tempest, Up-To-Date, and CME events (Peerview, OncLive, MJH, and others). TKC also has institutional patents filed on molecular mutations and immunotherapy response and ctDNA (U.S. patent application no. 16/475,574 and U.S. provisional patent application no. 63/093,616), as well as equity in Tempest, Pionyr, Osel, and NuscanDx, and serves on committees for the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology/European Society of Medical Oncology, and Academic & Community Cancer Research United. TKC has mentored several nonUS citizens on research projects with potential funding (in part) from non-US sources and/or foreign components. JML holds stock or other ownership interests in Salus Discovery LLC, which has licensed technology used within this study. SGZ has pending patent applications on molecular signatures in prostate cancer unrelated to this work licensed to Veracyte (U.S. patent publication nos. US20190218621A1, US2021130902A1, and US2021317531A1). SGZ's spouse is an employee of Exact Sciences and has been compensated with restricted stock units. WH is a cofounder of PathomIQ and owns equity in this company. MET is on the advisory board and receives honoraria from Janssen, Bayer, Astellas, AstraZeneca, Abbvie, Arcus Biosciences, Myvant, Roviant, and Blue Earth. XXW recieves advisory board honoraria from Novartis and research support (institutional) from Bristol-Myers Squibb. DJB holds equity in Bellbrook Labs LLC, Tasso Inc., Salus Discovery LLC (which has licensed technology used within this study), Lynx Biosciences Inc., Stacks to the Future LLC, Flambeau Diagnostics LLC, and Onexio Biosystems LLC. HE is an advisory board member for Bristol-Myers Squibb. Exelixis. Cardinal Health. and Seattle Genetics, and receives research funding from Bristol-Myers Squibb, Exelixis, Replimune, Merck, Calithera, and Roche/Genentech. HIS is a compensated consultant for/advisor to Ambry Genetics Corp., Konica Minolta Inc., Bayer, Pfizer Inc., Sun Pharmaceuticals, WCG Oncology and an uncompensated consultant/advisory to Amgen, Janssen Research & Development LLC, and Janssen Biotech Inc. HIS receives reviewers fees from Elseiver Ltd. and honoraria from Arsenal Capital; has received research funding (to his institution) from AIQ Solutions, Epic Sciences, Illumina Inc., Janssen, Menarini Silicon Biosystems, Prostate Cancer Foundation, and Thermo Fisher Scientific; and is supported in part by SPORE in Prostate Cancer grant P50 CA092629 (Memorial Sloan Kettering Cancer Center), HIS also has intellectual property rights with BioNTech, Elucida Oncology, MaBVAX. and Y-mAbs Therapeutics Inc., and nonfinancial support from Amgen, Bayer, Epic Sciences, Promontory Therapeutics (formerly Phosplatin), Pfizer Inc., Prostate Cancer Foundation, and WCG Oncology.

SUPPLEMENTAL METHODS - ANALYTICAL VALIDATION

Cell Line

The human CRPC cell line 22RV1 was maintained in cell culture flasks in 10% FBS with 5% penicillin/streptomycin in RPMI at 37C with 5% CO₂. 22RV1 22Rv1 (ATCC Cat# CRL-2505, RRID:CVCL 1045) were a gift from Scott Dehm and were authenticated in 2017 by the Wisconsin Translational Research Initiatives at the Pathology Laboratory at the University of Wisconsin. In order to count cell line cells prior to mRNA extraction, cells were first stained with Calcein AM by incubating them for 15 minutes at 37°C in 1:1000 Calcein AM in PBS. Cells were then washed and counted with a hemocytometer to obtain 100 total cells. After cells were incubated for 30 minutes at 4°C with antibody-coated PMPs, they were placed in an imaging chamber constructed of a silicone isolator (EMS Diasum, #70348-44) adhered to a glass coverslip (Chemglass, Life Sciences, #CLS17622575) for exact enumeration using fluorescence microscopy imaging. Each imaging chamber (~7x7mm²) was imaged at 10x magnification on an inverted fluorescence microscope with an automated XYZ stage (Nikon Instruments, Inc) using a snaking grid-like pattern of smaller image tiles (~1mm²). Uniform focus was maintained across the imaging field with NIS Elements Perfect Focus System (PFS). The imaging chamber was then placed on the ExtractMax platform (Gilson Inc., and Salus Discovery, LLC) for cell capture, using a 4 slide FlexWell tray (EMS diasum) to stabilize the chamber. Cells were pulled from the imaging chamber into the lysis well, then a second picture was acquired of the original imaging chamber to determine the exact quantity of cells effectively captured and lysed with the ExtractMax, NIS-Elements AR Microscope Imaging Software (RRID:SCR 014329, Nikon Instruments, USA)binary thresholding algorithms were used to automatically identify and count the number of cells in each image. After reverse transcription, the cDNA was then serially diluted to equivalents of 12, 7, 4, 2.5, 1.5, 1.2, 0.9, 0.7, 0.5, 0.4, 0.3, 0.2, 0.1, 0.06, and 0.03 cells, then split into separate replicate aliquots for downstream PreAmp and gPCR.

Automated mRNA Extraction

Prior to use, mRNA extraction plates and strips (Gilson, Inc) were briefly submerged in RNAse away (Life Tech), rinsed with nuclease-free distilled water (Thermofisher Scientific), and allowed to air dry. mRNA was extracted from captured CTCs by incubating them for 5 minutes at room temperature in 10% Lysis Binding Buffer (LBB) (Dynabeads mRNA DIRECT, Thermofisher Scientific) diluted in PBS containing 10uL Dynabeads Oligo(dT)25 beads (washed once with 10% LBB prior to use). The PMPs were collected then transferred through one sequential wash of wash buffer A (WBA) and one of 1% PBST then eluted into molecular grade nuclease-free water (Promega, Inc). Additional details can be found in a prior publication using this method(1).

Oligonucleotide Standards

DNA oligonucleotides (oligos) were designed as DNA sequences specific to the amplified region of each of the primer pairs included in the multi-target panel to serve as contrived sample material to evaluate the performance of the PreAmp and qPCR steps of the assay. All DNA oligos were designed by Thermo Fisher Scientific and purchased from Integrated DNA Technologies then prepared at 100 uM in TE buffer and stored at -20°C. Several different DNA Oligo serial dilutions were prepared on different days to obtain a balance of replicate sets with a mixture of replicates with both detected and undetected signal. The different uM concentrations of the different serial dilution levels were as follows: SYP (1E-12, 1E-13, 1E-14, 1E-15, 1E-16, 1E-17); CHGA (1E-10, 1E-11, 1E-12, 1E-13, 1E-14, 1E-15); AR-V9 (1E-9, 1E-10, 1E-11, 1E-12, 1E-13, 1E-14, 1E-15); KLK3 (1E-10, 1E-11, 1E-12, 1E-13, 1E-14, 1E-15); TMPRSS2 (1E-10, 1E-11, 1E-12, 1E-13, 1E-14, 1E-15); FOLH1 (1E-10, 1E-11, 1E-12, 1E-13, 1E-14, 1E-15)

CHGA:

SYP:

5'GGATTGTGCCAACAAGACCGAGAGTGACCTCAGCATCGAGGTCGAGTTCGAGTACCCCTTCAGGCTGC ACCAAGTGTACTTTGATGCACCCACCTGCCGAGGGGGCACCACCAAGGTCTTCTTAGTT 3'

AR-V7:

5'GATAAATTCCGAAGGAAAAATTGTCCATCTTGTCGTCTTCGGAAATGTTATGAAGCAGGGATGACTCTGG GAGAAAAATTCCGGGTTGGCAATTGCAAGCATCTCAAAATGACCAGACCCTGAAGAAAGGCTGACTTGCC TCATTCAAAATGAGG 3'

AR-V9:

5'AGCAGTGATCTCGGAAATGTTATGAAGCAGGGATGACCCGCGTGCGAGATAAAAATACTAGGTAACTAG AGGGACTGCGACGTTCTAAACGTTGGCTGGGAGACAACTTACTCCGTCAGAAGCGCCATCCAGGATCAC GTTACCCCGAAAAAGACATTTGCACATCTTTTGGGATCAAAGATATCA 3'

KLK3:

5'AGCCCCAAGCTTACCACCTGCACCCGGAGAGCTGTGTCACCATGTGGGTCCCGGTTGTCTTCCTCACC CTGTCCGTGACGTGGATTGGTGCTGCACCCCTCATCCTGTCTCGGATTGTGGGAGGCTGGGAGTGCGAG AAGCATTCCCAACCCTGGCAGGTGCTTGT 3'

TMPRSS2:

5'CTTACAGACCAGGAGTGTACGGGAATGTGATGGTATTCACGGACTGGATTTATCGACAAATGAGGGCAG ACGGCTAATCCACATGGTCTTCGTCCTTGACGTCGTTTTACAAGAAAACAATGGGGCTGGTTTT 3'

FOLH1:

5'AGATTTTCAACACATCATTATTTGAACCACCTCCTCCAGGATATGAAAATGTTTCGGATATTGTACCACCT TTCAGTGCTTTCTCCTCAAGGAATGCCAGAGGGCGATCTAGTGTATGTTAACTATGCACGAACTGAAGA CTTCTTTAAATTGGAACGGGACATGAAAATCA 3'

KLK2:

5'GATGGGCACACTGTGGGGGTGTCCTGGTGCACCCCCAGTGGGTGCTCACAGCTGCCCATTGCCTAAAG AAGAATAGCCAGGTCTGGCTGGGTCGGCACAACCTGTTTGAGCCTGAAGACACAGGCCAGAGGGTCCCT GTCAGCCACA 3'

Patient Sample Processing

Peripheral blood was collected from patients with metastatic prostate cancer under University of Wisconsin IRB approved protocol (2014-1214)(2). The protocol allowed a maximum of 50mL of blood collected in a single blood draw using EDTA vacutainers (BD Biosciences) and processed within 24 hours of collection allowing for duplicate samples for validation studies. Equivalency of mRNA yield was confirmed between blood processed immediately after draw compared to blood processed after overnight incubation at room temperature. 15 mL of blood was used for CTC isolation. Whole blood was diluted 1:1 with phosphate buffered saline (PBS, Hyclone) and 30mL of diluted blood was underlaid with 10mL of ficoll-paque PLUS (GE Healthcare) per 50mL conical tube. The blood was centrifuged for 20 minutes at 974g and harvested peripheral blood mononuclear cells (PBMCs) were washed twice with 50mL PBS. PBMCs were then depleted of CD45+ cells with standard LS columns per manufacturer's instructions (Miltenyi Biotec). The samples were divided into replicates after CTC capture isolation and RNA extraction, but before pre-amplification.

Paramagnetic Particle (PMP) Preparation

Streptavidin coupled PMPs (Sera-Mag Streptavidin-Blocked SpeedBeads, Cytiva) at a concentration of 50ug per reaction were used for all experiments. The PMPs were washed with 0.1%Tween-20 in PBS (0.1%PBST) prior to use then incubated under agitation with 1uL each of capture antibodies against EpCAM (R&D Systems, TROP1), MUC1 (Biolegend, 16A), and TROP2 (R&D Systems, AF650), biotinylated according to the manufacturer's recommendations (Dynabeads FlowComp Flexi Kit, Thermofisher Scientific). Prior to use, bead conjugates were washed and held in 10% FBS. Additional details can be found in prior publications using this method(1, 3).

CTC Isolation


CD45 depleted PBMCs were incubated on a rotator with antibody-labelled PMPs in a buffer containing 10%FBS for 30 minutes at 4°C with constant rotation. Cells bound to PMPs were isolated using automated ESP technology on the ExtractMax platform (Gilson Inc., and Salus Discovery, LLC) as described previously(2, 4). Briefly, PMP-bound cells were moved with magnetic manipulation through three 10% FBS wash wells before cell lysis for mRNA extraction.

RT-qPCR


The eluted mRNA sample was reverse transcribed using the high-capacity RNA to cDNA Reverse Transcription Kit (Thermofisher Scientific) according to the manufacturer's directions. cDNA was combined with TaqMan PreAmp master mix (Thermofisher Scientific) and TaqMan primers diluted 1:100 in TE buffer (Promega), and then subjected to 10 cycles of pre-amplification (PreAmp) according to the manufacturer's directions. The amplified product was then diluted 1:5 in TE buffer and combined with iTaq Universal Probes Supermix (Bio-Rad Laboratories) and the commercial TaqMan primers for these genes for 45 cycles of qPCR (CFX Connect Real-Time PCR Detection System, Bio-Rad Laboratories). The primers for AR-V9 were not commercially available but have been published previously(2, 5).

SUPPLEMENTAL REFERENCES

- 1. Pezzi HM, Guckenberger DJ, Schehr JL, Rothbauer J, Stahlfeld C, Singh A, et al. Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extraction. *Lab Chip.* 2018;18(22):3446-58.
- 2. Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, et al. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. *J Clin Oncol.* 2021:JCO2100169.
- 3. Pezzi HM, Niles DJ, Schehr JL, Beebe DJ, and Lang JM. Integration of Magnetic Bead-Based Cell Selection into Complex Isolations. *ACS Omega*. 2018;3(4):3908-17.
- 4. Casavant BP, Guckenberger DJ, Beebe DJ, and Berry SM. Efficient sample preparation from complex biological samples using a sliding lid for immobilized droplet extractions. *Anal Chem.* 2014;86(13):6355-62.
- 5. Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, et al. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. *Clin Cancer Res.* 2017;23(16):4704-15.



Supplemental Figure 1: In a subset of the serial samples from the NEPC patients in our institutional cohort, we had enumeration data. When we plot the per-sample NEPC CTC prediction vs. the enumeration data, we can see higher CTC numbers in the NEPC-positive compared to the NEPC-negative samples.



Supplemental Figure 2: PSA trends for the NEPC patients in our institutional cohort. Each sample is represented as a point, and a triangle indicates that the CTC molecular profiling suggested NEPC per the criteria described. Note that there were some missing PSA levels, primarily due to treating clinicians stopping PSA measurements once it was clear that PSA was no longer informative.

SUPPLEMENTAL TABLES

Supplemental Table 1

• •	UWCCC	ENZA-CRPC	AA-CRPC
Number patients	17	21	27
Age, year, median (IQR)	68 (63-78)	68 (62-72)	66 (59-74)
Race*	, ,	,	, ,
White	17 (100%)	12 (57.1%)	25 (92.6%)
Black or African American	0 (-)	2 (9.5%)	0 (-)
Asian	0 (-)	1 (4.8%)	0 (-)
Unknown	0 (-)	6 (28.6%)	2 (7.4%)
ECOG performance status			
0	10 (58.8%)	14 (66.7%)	20 (74.1%)
1	2 (11.8%)	7 (33.3%)	7 (25.9%)
NA	5 (29.4%)	0 (-)	0 (-)
PSA level, ng/mL, median (IQR)	12 (3-41)	24 (8-141)	13 (7-48)
<10	7 (41.2%)	8 (38.1%)	9 (33.3%)
10-20	2 (11.8%)	1 (4.8%)	7 (25.9%)
≥20	8 (47.1%)	12 (57.1%)	10 (37.0%)
NA	0 (-)	0 (-)	1 (3.7%)
Gleason score			
≤6	3 (17.6%)	3 (14.3%)	1 (3.7%)
7	4 (23.5%)	7 (33.3%)	11 (40.7%)
8-10	6 (35.3%)	10 (47.6%)	13 (48.1%)
NA	4 (23.5%)	1 (4.8%)	2 (7.4%)
Metastases at diagnosis	7 (41.2%)	4 (19.0%)	8 (29.6%)
Prior abiraterone acetate	1 (5.9%)	1 (4.8%)	0 (-)
Prior enzalutamide**	0 (-)	0 (-)	4 (14.8%)
Prior chemotherapy	3 (17.6%)	10 (47.6%)	11 (40.7%)
Prior ketoconazole	1 (5.9%)	2 (9.5%)	2 (7.4%)
Prior sipuleucel-T	1 (5.9%)	5 (23.8%)	6 (22.2%)
Sites of metastasis			
Bone	16 (94.1%)	19 (90.5%)	0 (-)
Liver	5 (29.4%)	0 (-)	1 (3.7%)
Lung	3 (17.6%)	5 (23.8%)	0 (-)
Lymph Nodes	12 (70.6%)	11 (52.4%)	7 (25.9%)
Others	3 (17.6%)	3 (14.3%)	0 (-)

Values are n (%) or median (IQR).

^{*}Patient determined.

^{**}Prior enzalutamide and abiraterone excluded from ENZA-CRPC and AA-CRPC, respectively.

Supplemental Table 2

ENZA-CRPC (NCT01942837)

Brigham and Women's Hospital

Dana-Farber Cancer Institute

Beth Israel Deaconess Medical Center

South Shore Hospital

University of Washington Medical Center/Seattle Cancer Care Alliance

AA-CRPC (NCT02025010)

Brigham and Women's Hospital

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center Basking Ridge

Memorial Sloan Kettering Cancer Center Commack

Memorial Sloan Kettering Cancer Center West Harrison

Memorial Sloan-Kettering Cancer Center

Memorial Sloan Kettering Cancer Center Rockville Centre

Memorial Sloan Kettering Cancer Center Sleepy Hollow

Seviteronel trial (NCT02445976)

University of Alabama

Mayo Clinic

University of California at Los Angeles

Yale University

Mayo Clinic - Jacksonville

Moffitt Cancer Center

Tulane University

Beth Israel Deaconess Medical Center

Dana-Farber Cancer Institute

Karmanos Cancer Institute

University of Minnesota

Washington University

GU Research Network

New Mexico Cancer Care Alliance

Memorial Sloan Kettering Cancer Center

University of North Carolina

Carolina Urologic Research Center

University of Virginia

Virginia Oncology Associates

University of Washington

University of Wisconsin Carbone Cancer Center

Boston, Massachusetts, United States, 02115
Boston, Massachusetts, United States, 02115
Boston, Massachusetts, United States, 02215
Weymouth, Massachusetts, United States, 02190
Seattle, Washington, United States, 98195

Boston, Massachusetts, United States, 02115
Boston, Massachusetts, United States, 02115
Basking Ridge, New Jersey, United States, 07920
Commack, New York, United States, 11725
Harrison, New York, United States, 10604
New York, New York, United States, 10065
Rockville Centre, New York, United States, 11510
Sleepy Hollow, New York, United States, 10591

Birmingham, Alabama, United States, 35249 Scottsdale, Arizona, United States, 85054 Los Angeles, California, United States, 90095 New Haven, Connecticut, United States, 06519 Jacksonville, Florida, United States, 32224 Tampa, Florida, United States, 33612 New Orleans, Louisiana, United States, 70112 Boston, Massachusetts, United States, 02215 Boston, Massachusetts, United States, 02215 Detroit, Michigan, United States, 48201 Minneapolis, Minnesota, United States, 55455 Saint Louis, Missouri, United States, 63110 Omaha, Nebraska, United States, 68130 Albuquerque, New Mexico, United States, 87106 New York, New York, United States, 10065 Chapel Hill, North Carolina, United States, 27514 Myrtle Beach, South Carolina, United States, 29572 Charlottesville, Virginia, United States, 22903 Hampton, Virginia, United States, 23666 Seattle, Washington, United States, 98109 Madison, Wisconsin, United States, 53715